Private: Fullwidth Portfolio Post

05

Jan2015
Common Drug Review The Canadian Agency for Drugs and Technologies in Health posted the Canadian Drug Expert Committee (CDEC) final recommendation for its first review of a subsequent entry biologic on its website yesterday. Below is an excerpt from the CDEC Final Recommendation. Recommendation: ... Read More

03

Oct2014
Common Drug Review patient input submission system CADTH has added new safeguards allowing them to better track submissions automatically: Online & email confirmations for successful uploads Submissions can now be uploaded until midnight on the date of the specified deadline, in all Canadian time zones   2015 CADTH Symposium CADTH is offering funding to help patient ... Read More

16

Sep2014
The Canadian Agency for Drugs and Technologies in Health (CADTH) revised its Guidelines for Manufacturers on Application Fees for the Common Drug Review. A draft version was circulated for stakeholder feedback in July, following which the below key changes were made: Fees for resubmission based on new clinical information ... Read More

06

Aug2014
Direct-Acting Antivirals for Chronic Hepatitis C Genotype 1: Draft recommendations posted, feedback requested Yesterday the Canadian Agency for Drugs and Technologies in Health (CADTH)posted on its website the draft Canadian Drug Expert Committee (CDEC) recommendations report stemming from itsrecent therapeutic review project to assess the clinical and economic impact ... Read More

31

Jul2014
The Canadian Agency for Drugs and Technologies in Health (CADTH) is requesting stakeholder feedback on its draft guidance document, released today, concerning its recent announcement to introduce industry application fees for manufacturer submissions and resubmissions made to the Common Drug Review. The draft Guidelines for Manufacturers on Application Fees ... Read More

30

Jul2014
An updated table with the targeted Canadian Drug Expert Committee (CDEC) meeting dates is now available on the CADTH website A CDEC meeting will be held in December 2014 as part of an initiative to eliminate an accumulation of CDR submissions. CADTH is extending the pilot process for receiving patient input ... Read More

08

Jul2014
Effective July 2, 2014, patient groups will now have 35 business days to prepare and submit their patient input submissions to CDR This is possible due to the mandatory pre-submission advance notice policy which will be going into effect the same day. As per the policy, manufacturers must provide a minimum ... Read More

26

May2014
CDR Consultation – Patient Input Template for Subsequent Entry Biologics (SEB) CADTH has developed a patient input template for SEBs and is now seeking feedback on the proposed template. Feedback should be emailed by June 6, 2014 to feedback@cadth.ca. Temporary Suspension of a CDR Review Due to Incomplete Information CADTH has recently encountered CDR submissions with ... Read More

24

May2014
Common Drug Review (CDR) introduces new application fee for submissions The Canadian Agency for Drugs and Technologies in Health (CADTH) is introducing an industry application fee for submissions made by drug manufacturers to CDR effective September 1, 2014 (April 1, 2015 for drugs submitted to the pan-Canadian Oncology Drug Review). All submissions with a ... Read More

22

May2014
CDEC will review and provide recommendations on reimbursement of drugs for rare diseases (DRDs) according to an enhanced Common Drug Review approach, as per news released today in CDR Update- Issue 103. CADTH incorporated suggestions from stakeholder feedback (invited in October ... Read More